Turn this list into pipeline.
Biotech Companies in Edinburgh: 65 Active Firms (2026)
Biotech companies in Edinburgh develop biology-led diagnostics, therapeutics and research platforms within the city's life-sciences cluster.
Procurement in this cohort tends to sit with scientific, clinical, regulatory and manufacturing teams rather than general IT or consumer marketing budgets. Buyers include healthcare organisations, laboratories, pharmaceutical and manufacturing groups, academic units and research customers in the UK and overseas. Engagements usually look like validation studies, research-tool supply, discovery collaborations, bioprocessing work or staged therapeutic and diagnostic development, with long diligence cycles and evidence requirements. The commercial profile is mixed: some firms show turnover scale, while others appear to operate capital-efficient R&D models with specialist staff and limited reported headcount.
Read more
Edinburgh has 65 actively trading biotech companies, giving the city a compact life-sciences cohort rather than a broad national market in miniature. Reported employment across the cohort is 1,861 people, so the employment footprint is not confined to founder-led research vehicles, even though the company count remains small. The local picture is therefore weighted towards specialist employers with clinical, laboratory and manufacturing touchpoints, alongside earlier commercial firms still proving repeatable demand.
Clinical translation brings the sector under the UK life-sciences rulebook rather than a dedicated biotech licence. The MHRA sets standards, reviews clinical trial applications and assesses marketing authorisations, while trials involving people must follow Good Clinical Practice, ethics review and informed-consent requirements. Pharmacovigilance continues after authorisation. Market access for approved medicines can involve health technology assessment before routine public use, so commercial planning often runs alongside evidence generation. Sector representation comes through bodies including the BioIndustry Association and the ABPI.
Edinburgh's biotech cohort appears likely to stay specialised, with demand shaped by clinical evidence, laboratory adoption and partner diligence rather than volume sales. Firms with validated platforms or regulated diagnostic workflows tend to have clearer routes into healthcare, pharmaceutical and research customers, but development timelines remain long and cash needs can rise before revenue catches up. The scarcity of larger revenue reporters suggests that scale-up remains the harder phase, while newer entrants may continue to rely on grants, collaborations and service income before committing to more capital-intensive clinical programmes.
65
Active firms
2026
5
Above £5M
revenue threshold
15
Incorporated since 2022
Key facts
About 7% of the trading cohort reports turnover above £5M (5 of 65 firms) — the rest sits below that revenue band.
23% of the cohort was incorporated since 2022 (15 firms), so a sizeable share is in its first few filing cycles.
The Office for Life Sciences estimated UK life-sciences turnover at £146.9 billion in 2023/2024.
Biopharmaceuticals accounted for 67% of UK life-sciences turnover in 2023/2024, with £98.9 billion across 2,960 companies.
The MHRA approves clinical trial applications, assesses marketing authorisations or drug licences, and monitors post-authorisation safety through pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements before products move towards NHS market access.
BIA reported that the UK biotech sector raised £3.5 billion in equity investment in 2024, a 94% increase on the previous year and below £4.5 billion in 2021.
Top Edinburgh biotech companies
MEDANNEX LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops antibody-based therapeutics targeting annexin‑A1 for the treatment of cancer and autoimmune diseases. Conducts preclinical research and clinical trials, including development of monoclonal…
Serves healthcare providers and clinical researchers through oncology and autoimmune disease studies, ultimately targeting cancer patients and people with autoimmune conditions. Also engages…
Financial Health
StableStable · -70% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops cell analysis technology for bioprocessing and cell therapy manufacturing. Its AuraCyt‑based Celledonia platform measures intrinsic cell properties without labelling to generate predictive…
Serves biopharmaceutical and cell therapy organisations, particularly bioprocessing and cell line development teams working on monoclonal antibodies, viral vectors, and allogeneic or autologous cell…
Financial Health
StrongStrong · Hiring · 32% CAGR over 4y
Location
WOBBLE GENOMICS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops RNA sequencing technologies and diagnostic platforms for detecting nucleic acid biomarkers from blood. Combines biochemical methods and bioinformatics software to identify low‑abundance…
Serves healthcare and life sciences organisations involved in cancer diagnostics, biomarker discovery and disease monitoring, with cancer patients as the end beneficiaries.
Financial Health
StrongStrong · Growing, Hiring · 52% CAGR over 3y
Location
BIOCAPTIVA LIMITED
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsDevelops polymer-based materials for capturing cell‑free DNA (cfDNA) from biological fluids. Its msX polymers can be applied to beads, foams and surfaces to collect and stabilise samples for liquid…
Serves diagnostics companies, clinical laboratories, research organisations and healthcare providers developing liquid biopsy, non-invasive genetic testing and personalised medicine workflows,…
Financial Health
StrongStrong
Location
LARIO THERAPEUTICS LIMITED
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops precision medicines for neurological disorders, focusing on disease‑modifying therapies for epileptic conditions and Parkinson’s disease. Conducts biopharmaceutical research and preclinical…
Targets patients, clinicians and healthcare systems dealing with severe neurological disorders, especially developmental and epileptic encephalopathies in children and Parkinson’s disease, PTSD and…
Financial Health
StrongStrong
Location
Microbira Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops artificial intelligence software that analyses Fourier transform infrared spectroscopy data to identify microorganisms. Provides a cloud‑based platform and spectral databases enabling rapid…
Sells to small-to-large clinical microbiology laboratories, healthcare providers, research teams, food safety and environmental microbiology organisations, and veterinary laboratories.
Financial Health
StrongStrong · Hiring · 41% CAGR over 2y
Location
Develops, manufactures and markets diagnostic testing products focused on food sensitivity and gut health. Produces immunoassay-based test kits and laboratory diagnostics used by healthcare…
Serves healthcare practitioners, nutrition and functional medicine professionals, and medical laboratories worldwide, with distributors and commercial partners in emerging markets; patients are…
Location
ONCOBIOPHARM LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops therapeutic antibodies targeting cellular control pathways involved in cancer and other diseases. Its lead candidate, Tensinumab (ATN‑E11), is a human antibody designed to inhibit tumour…
Financial Health
WeakWeak · Hiring · 6% CAGR over 4y
Location
FULDERM INTERNATIONAL LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises fulvic acid–based dermatology products and medical devices, including topical treatments for conditions such as atopic dermatitis. Supports clinical research and…
Targets the healthcare and consumer dermatology market, including people with mild to moderate atopic dermatitis and EU-based pharmacy, clinical and distribution channels.
Financial Health
StrongStrong · Hiring · 5% CAGR over 4y
Location
MACOMICS LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsConducts drug discovery research focused on macrophage biology, developing therapeutic candidates that modulate macrophage activity for diseases where existing treatments are limited or ineffective,…
Targets pharmaceutical and biotechnology partners, investors, and healthcare stakeholders interested in macrophage-focused therapeutics for diseases with limited treatment options.
Financial Health
StableStable · Hiring · 21% CAGR over 1y
Location
Caritas Bioscience Ltd
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsProvides clinical research organisation (CRO) services for pharmaceutical and biotechnology studies, including clinical trial design, protocol development, regulatory and ethics submissions,…
Serves healthcare and life sciences organisations running clinical trials, particularly small pharma and biotech companies seeking CRO support from clinical operations leaders, study teams and…
Financial Health
WeakWeak · -24% CAGR over 4y
Location
MI:RNA LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops an AI-based diagnostic platform using microRNA biomarkers to detect diseases in animals before clinical symptoms appear. Focuses on tests for companion and production animals, including…
Sells to veterinary and animal health markets, serving companion animal care providers and production animal stakeholders such as cattle farmers and herd managers. Also targets laboratory partners…
Financial Health
HealthyHealthy · Hiring · 68% CAGR over 4y
Location
Actual Analytics Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies automated home‑cage monitoring systems for laboratory animal research. Its Home Cage Analyser technology tracks activity and behaviour of socially housed rodents continuously,…
Sells to B2B research organisations using rodents in vivariums, including preclinical and behavioural researchers in pharma, biotech and related life sciences seeking continuous home-cage monitoring…
Financial Health
HealthyHealthy · Hiring · 24% CAGR over 4y
Location
Ogi Bio Ltd
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies automated, modular bench‑top bioreactor systems for culturing and analysing microbial organisms such as bacteria, yeast and algae. Systems automate small‑scale fermentation…
Sells to scientists and laboratory teams conducting microbial research and development, including academic institutions and biotech organisations working with bacteria, yeast, algae and bacteriophage…
Financial Health
StrongStrong · Growing, Hiring · 15% CAGR over 4y
Location
SAMASTAR LTD
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops automation technology for bioprocessing laboratories, including systems for automated monitoring of microbial cultures, remote measurement of microbial growth, and real-time data analysis to…
Serves biotech and bioprocessing research labs, including researchers and R&D teams monitoring microbial cultures in academic or industrial laboratory settings.
Financial Health
DistressedDistressed · -15% CAGR over 2y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides bioinformatics data analysis and biological interpretation for pharmaceutical, biotechnology and academic research. Analyses genomic, transcriptomic, proteomic and other biological datasets,…
Serves pharmaceutical and biotechnology companies, CROs, life science researchers and academic organisations undertaking drug discovery, development and applied biological research.
Financial Health
StableStable · 2% CAGR over 2y
Location
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies laboratory instruments and analysis software that measure motion and particle dynamics at micro‑ and nanoscale. Products analyse semen quality for livestock fertility and…
Serves B2B customers in livestock reproduction, fermentation, chemicals, pharmaceuticals and biotechnology, including bull studs, on-farm fertility teams, formulation scientists and partners…
Financial Health
HealthyHealthy
Location
LESS GREY IMAGING LIMITED
Trajectory
1y · 2025–NowDevelops medical imaging software that processes contrast‑enhanced ultrasound data to generate super‑resolution images of prostate microvasculature, supporting detection, localisation and clinical…
Serves healthcare providers and clinicians involved in prostate cancer diagnosis, including urologists, radiologists and hospitals using clinical ultrasound for assessment, biopsy triage and…
Financial Health
Insufficient historyInsufficient history
Location
PHASER BIOMEDICAL LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
HealthyHealthy · Hiring · 66% CAGR over 1y
Location
Danu Insights Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops artificial intelligence software for designing and optimizing scientific experiments in life sciences, supporting biotechnology and clinical research teams with data analysis and tools to…
Serves B2B life sciences organisations, including biotech companies and clinical research teams conducting experimental R&D.
Financial Health
StableStable · Hiring · 150% CAGR over 1y
Location
Quantics Consulting Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProvides biostatistical consulting and software for the life sciences and medical device sectors. Supports bioassay analysis, clinical trial design and analysis, PK/PD modelling, health technology…
Serves B2B life sciences and medical device organisations, including biotech, pharmaceutical and vaccine developers running bioassays, clinical trials, HTA submissions and regulated research across…
Financial Health
HealthyHealthy · Hiring · 3% CAGR over 3y
Location
Hydrosense Limited
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and supplies rapid on‑site test kits for detecting Legionella pneumophila in water systems and biofilm. Products include swab and water testing kits and industrial testing packs used to…
Serves B2B customers responsible for water safety, including water treatment and environmental service providers, facilities managers and healthcare organisations managing Legionella risk.
Financial Health
StableStable · -10% CAGR over 1y
Location
Endocryne Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
PHARMATICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops artificial intelligence software for biomedical and clinical research, transforming scientific publications and clinical trial data into predictive models. Provides evidence‑based medical…
Serves B2B organisations developing digital and precision health products, including health-tech software/app teams and preclinical or clinical research groups needing biomedical AI and API…
Financial Health
WeakWeak · 0% CAGR over 4y
Location
Kyrexa Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
Prozymi Biolabs Ltd
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
DistressedDistressed
Location
NIWALEN LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
C-Source Renewables Limited
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
DistressedDistressed · 0% CAGR over 3y
Location
BIOMARA LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak · Hiring · 41% CAGR over 2y
Location
DESTINA GENOMICS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · Hiring · 11% CAGR over 4y
Location
Excellio Labs Limited
Trajectory
1y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
Mycobiologics Limited
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
Rostra Therapeutics Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed
Location
Flcmc Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · 0% CAGR over 4y
Location
CONCINNITY GENETICS LTD
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
NIPHT Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops adeno-associated virus (AAV) gene therapy technologies and therapeutics for genetic and complex diseases. Conducts vector discovery and engineering, operates manufacturing platforms, and…
Serves patients with rare genetic and complex disorders, alongside clinical researchers, healthcare professionals, advocacy groups and biopharma collaborators involved in gene therapy research and…
Financial Health
StrongStrong · Growing · 2% CAGR over 2y
Location
Edinburgh Genetics
Trajectory
4y · 2021–NowDevelops in‑vitro diagnostic medical devices and provides genomic sequencing services, including whole genome, exome, targeted and RNA sequencing, metagenomics and bioinformatics. Also supports…
Serves life science, healthcare and diagnostics organisations, including clinical trial sponsors, genomic laboratories, biotech researchers, and teams in agriculture, conservation, oncology,…
Financial Health
Insufficient historyInsufficient history
Location
INGENZA LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops biocatalysis and engineering biology processes for pharmaceutical and industrial biotechnology. Provides strain and cell line development, biochemical route design, process and analytical…
Serves pharmaceutical and biotechnology companies developing biologics, small molecules and sustainable bioprocesses, including drug discovery teams, biomanufacturers and industrial customers…
Financial Health
StrongStrong · Hiring · 6% CAGR over 4y
Location
Almac
Provides contract pharmaceutical development and manufacturing services, including small‑molecule API development and production, peptide and protein synthesis, biocatalysis and analytical support,…
Serves pharmaceutical and biotechnology companies, from emerging biotechs to global biopharma, with drug development programmes spanning small molecules, peptides, precision medicine diagnostics and…
Location
PROFACTOR PHARMA LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops recombinant factor VIII (FVIII) therapies for the treatment of haemophilia A. Focuses on biotechnology research and manufacturing approaches aimed at producing lower‑cost FVIII and improved…
Serves haemophilia A patients, particularly the large undertreated population receiving inadequate or no treatment, through the haemophilia care market.
Financial Health
DistressedDistressed · 0% CAGR over 4y
Location
FLEXMEDICAL SOLUTIONS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsProvides design, development and manufacturing services for point‑of‑care diagnostic devices. Specialises in biosensors, microfluidic test cartridges, electrodes and assay systems, supporting clients…
Serves B2B medtech, diagnostics and life sciences organisations developing point-of-care diagnostic tests, biosensors, microfluidic cartridges and wearables, from early-stage innovators to…
Financial Health
StrongStrong · Growing, Hiring · 12% CAGR over 3y
Location
DEEP LIFE MEDICAL LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops medical devices and plant‑derived pharmaceutical treatments. Products include antiviral face masks, ventilator validation simulators, and postoperative gel products, while conducting…
Serves healthcare organisations, hospitals, clinical researchers and patients involved in trials for respiratory care, surgical recovery, sickle cell disease and arthritis treatments.
Financial Health
HealthyHealthy · -7% CAGR over 4y
Location
ICON RESEARCH LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides outsourced clinical research and development services for pharmaceutical, biotechnology and medical device companies, including clinical trial management, laboratory services, regulatory…
Serves pharmaceutical, biotechnology and medical device companies, as well as government and public health organisations involved in clinical research, drug development and therapeutic evidence…
Financial Health
StableStable · -70% CAGR over 4y
Location
Biotangents Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops molecular diagnostic tests for detecting infectious diseases in livestock. Products include laboratory assays for pathogens such as bovine viral diarrhoea virus and mastitis‑causing…
Serves veterinary diagnostic laboratories, cattle and dairy farms, and animal health distributors needing infectious disease testing for livestock, particularly bovine mastitis and BVD.
Financial Health
StableStable · 0% CAGR over 4y
Location
Qufora Ltd
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDesigns and manufactures medical devices for bowel and urology care, including bowel irrigation systems used to manage chronic constipation and faecal incontinence, supplying products for patients…
Serves people with chronic bowel conditions and healthcare professionals supporting bowel management, including users affected by chronic constipation or faecal incontinence across age groups.
Financial Health
HealthyHealthy · Profitable, Hiring · 9% CAGR over 3y
Location
ORIGIN PEPTIDES LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · Hiring · 14% CAGR over 4y
Location
Scottish Bioenergy Cooperative Ventures Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and produces algae‑derived natural ingredients using biotechnology, including phycocyanin blue food colouring, spirulina-based proteins, and nutritional compounds. Supplies colourants, plant…
Serves B2B customers in food, beverage, cosmetics and biotech research sectors, including product developers, manufacturers, academics and businesses seeking natural ingredient inputs.
Financial Health
StableStable · 2% CAGR over 4y
Location
Mauchline Science Consultants Limited
Trajectory
5y · 2021–NowFinancial Health
Insufficient historyInsufficient history
Location
Unlock all 65 leads
Showing 49 of 65 — +16 more with verified decision-maker contacts, live data, and CRM sync.
How Edinburgh biotech companies work and how to sell to them
What they do
Biotech firms usually monetise intellectual property, scientific services or regulated products rather than high-volume software subscriptions. Revenue can come from discovery collaborations, assay development, diagnostic testing, reagent or research-tool supply, contract bioprocessing, grant-funded projects, licence fees, staged milestone payments and eventual royalties. Early engagements often begin as paid feasibility work or validation studies, then expand if the biology, workflow or manufacturing process holds up under partner scrutiny. Pricing tends to follow project fees, full-time-equivalent research rates, sample or test volume, or negotiated rights to use a platform in defined applications.
Who they sell to
Typical buyers are technical and evidence-led: pharmaceutical groups, laboratory operators, healthcare organisations, manufacturers, academic research units and specialist distributors. The first sponsor may be a principal investigator, translational science lead, head of R&D, lab director, clinical operations manager or manufacturing lead, while procurement, quality, finance and legal teams usually enter before signature. Sales cycles tend to be long because buyers need validation results, regulatory comfort, intellectual-property review and internal budget approval. Direct scientific selling is common, with formal procurement or RFP routes more likely when clinical, manufacturing or public-sector work is involved.
What they buy
Most biotech firms tend to spend on laboratory operations, regulated workflow control and specialist advice before general corporate tooling. Relevant categories include laboratory information management, electronic lab notebooks, sample tracking, quality management, regulatory documentation, clinical trial administration, pharmacovigilance support, bioinformatics, secure data storage, cybersecurity and finance systems. Many also buy intellectual-property legal work, regulatory consultancy, grant support, accounting, audit, specialist insurance, scientific recruitment, contract research and contract manufacturing capacity. Sellers should expect buying criteria to include validation effort, audit trails, data integrity, traceability, permissioning and whether the supplier can work with scientific staff rather than only central operations teams.
Why and how to sell to them
Biotech buyers tend to evaluate suppliers when a research programme moves from exploratory work into validation, regulated development, partner diligence or manufacturing transfer. Other useful triggers include new scientific or quality leadership, fresh grant or equity funding, laboratory expansion, the first material service revenues, preparation for clinical work, or a collaboration with a larger life-sciences customer. Pain points are usually evidence burden, fragmented lab records, cash runway, reproducibility, audit readiness, sample traceability and slow procurement. Outbound that speaks to risk reduction, cleaner documentation, partner-ready reporting and lower operational drag is usually more credible than a broad productivity claim.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Edinburgh
Related directories
Frequently asked questions
How many biotech companies are there in the Edinburgh?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Edinburgh?↓
What do biotech companies in the Edinburgh actually do?↓
How does Edinburgh biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Edinburgh?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 65 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.